Chargement en cours...
Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer
In the last few years, the survival of patients with castration-resistant prostate cancer (CRPC) has significantly improved as a result of the development of second-generation androgen deprivation therapies such as abiraterone and second-generation antagonists such as enzalutamide. However, CRPC pat...
Enregistré dans:
| Publié dans: | Endocrinology |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Endocrine Society
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5460940/ https://ncbi.nlm.nih.gov/pubmed/28368512 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/en.2017-00109 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|